Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension

NCT00631917 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00631917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00631917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
February 29, 2008
Completion date
September 30, 2009
Enrollment
774 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension